Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · March 04, 2019

Efficacy and Safety of Switching to Ixekizumab in Secukinumab Nonresponder Patients With Psoriasis

The British Journal of Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The British Journal of Dermatology
Efficacy and Safety of Switching to Ixekizumab in Secukinumab Nonresponder Patients With Psoriasis: Results From a Multicentre Experience
Br J Dermatol 2018 Dec 22;[EPub Ahead of Print], A Conti, F Peccerillo, P Amerio, A Balato, F Bardazzi, L Bianchi, M Burlando, SP Cannavò, A Chiricozzi, P Dapavo, C De Simone, MC Fargnoli, A Gambardella, P Gisondi, P Malagoli, G Malara, C Mugheddu, AM Offidani, S Piaserico, F Prignano, L Stingeni, G Pellacani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading